Neem Skin Randomized Trial: What the Evidence Says

Quick Answer

Neem Skin Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The high cost, limited availability, and side effects associated with conventional treatments drive this preference among resource-limited populations. [Anning Alberta Serwah (2026); evidence level 1]
• Herbal materials, found in medicines, have gained popularity due to their strong antimicrobial properties and primary healthcare benefits. [Brar Gursahib Singh (2025); evidence level 3]
• These compounds exhibit diverse pharmacological activities, including anti-inflammatory, antimicrobial, antioxidant, and wound-healing properties.,As a result, herbal creams are utilized in treating conditions such as atopic dermatitis, psoriasis, acne vulgaris, rosacea, and skin ageing. [Brar Gursahib Singh (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For neem skin randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Anning Alberta Serwah (2026). Plant-based therapeutics for leishmaniasis: A systematic review emphasizing human studies and clinical trial evidence. DOI: 10.1371/journal.pntd.0014389. PMCID: PMC13240915. PMID: 42247419. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13240915/
• Brar Gursahib Singh (2025). Antimicrobial and Anti-Infective Potential of Herbal Creams in Dermatology: Efficacy, Safety, and Challenges in Skin Infection Management. DOI: 10.2147/IDR.S565852. PMCID: PMC12682302. PMID: 41362433. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12682302/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.